Research Activity & Clinical Trials

1. 2023 – A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ANB032 in the treatment of subjects with moderate to severe atopic dermatitis

2. 2023 – A phase 3, multicenter, double-blind maintenance study to assess long-term safety, tolerability, and efficacy of rocatinlimab in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) (ROCKET-ASCEND)

3. 2023 – A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis

4. 2023 – An open-label extension study to evaluate the long-term safety and efficacy of ESK-001 in patients with plaque psoriasis

5. 2023 – A phase 3, double-blind, randomized, placebo-controlled, efficacy and safety study of povorcitinib (INCB054707) in participants with moderate to severe hidradenitis suppurativa (STOP-HS2)

6. 2023 – A phase 3b/4 randomized, open-label, efficacy assessor blinded study, comparing the safety and assessor blinded efficacy of upadacitinib to dupilumab in subjects with moderate to severe atopic dermatitis (Level-Up)

7. 2023 – A phase 3, randomized, 24-week, placebo-controlled, double-blind study to assess the efficacy, safety, and tolerability of rocatinlimab (AMG 451) in combination with topical corticosteroids and/or topical calcineurin inhibitors in adult subjects with moderate-to-severe atopic dermatitis (AD)

8. 2023 A phase 1/2, randomised, placebo-controlled study of EDP2939 in healthy volunteers and participants with moderate plaque psoriasis

9. 2023 A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ESK-001 in patients with moderate to severe plaque psoriasis

10. 2022 – 2023 A phase 3b, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of guselkumab for the treatment of participants with skin of color who have moderate-to-severe plaque psoriasis and/or moderate-to-severe scalp psoriasis

11. 2022 – 2023 A phase 2a, open label, proof-of-concept trial of daxdilimab for the treatment of moderate to severe alopecia areata

12. 2022 – 2023 A randomized, double-blinded, placebo-controlled, phase 2a study to evaluate the efficacy and safety of RIST4721 in subjects with hidradenitis suppurativa

13. 2022 A phase 3, 4-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-151 cream 0.15% administered QD in subjects with atopic dermatitis

14. 2022 – 2023 A phase 3, multicenter, open-label extension study of the long-term safety of ARQ-151 cream 0.15% and ARQ-151 cream 0.05% in subjects with atopic dermatitis

15. 2021 – 2022 A multicenter, open-label, extension study to assess the long-term safety and efficacy of CTP-543 in adult patients with moderate to severe alopecia areata

16. 2021 – 2023 A phase 2, multicenter, global, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of cendakimab (CC-93538) in adult subjects with moderate to severe atopic dermatitis

17. 2021 – 2022 A phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-154 foam 0.3% administered QD in subjects with scalp and body psoriasis (ARRECTOR)

18. 2021 – 2022 A phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa

19. 2021 – 2023 A phase 4 multicenter, randomized, open-label, efficacy assessor-blinded study of isankizumab compared to apremilast for the treatment of adult subjects with moderate plaque psoriasis who are candidates for systemic therapy

20. 2021 – 2022 A phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-154 foam 0.3% administered QD in subjects with seborrheic dermatitis (STRATUM)

21. 2021 – 2023 A randomized, double-blind and placebo-controlled phase 3 study to evaluate efficacy and safety of oral SHR0302 in subjects aged 12 years and older with moderate to severe atopic dermatitis

22. 2021 – 2023 A multicenter, randomized, double-blinded study evaluating the pharmacokinetics, efficacy and safety of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in subjects with moderate to severe plaque psoriasis

23. 2021 A phase 2a, proof of concept, 24-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 cream 0.3% in subjects with non-segmental facial vitiligo

24. 2021 – 2022 A multicenter, open-label, randomized study to assess the pharmacokinetics, safety, and efficacy of two doses of bimekizumab in adolescent study participants with moderate t severe plaque psoriasis

25. 2021 – A long-term study to assess the safety and efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis

26. 2021 – 2022 A prospective, multicenter, long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with moderate-to-severe atopic dermatitis

27. 2020 – 2022 A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata

28. 2020 – 2021 A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab when used in combination with topical corticosteroid treatment in patients with moderate-to-severe atopic dermatitis

29. 2020 – 2023 A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with moderate-to-severe atopic dermatitis

30. 2020 – 2022 A phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in study M16-046

31. 2020 A phase 1/2b, multiple dose and 12-week, parallel group, double blind, dose ranging, vehicle-controlled study of the safety and efficacy of ARQ-252 cream 0.1% and ARQ-252 cream 0.3% in subjects with chronic hand eczema

32. 2020 – 2023 A phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa

33. 2020 – 2022 A phase 3, multicenter, open-label extension study of the long-term safety of ARQ-151 cream 0.3% in subjects with chronic plaque psoriasis who have completed preceding studies ARQ-151-301 or ARQ-151-302

34. 2020 – 2021 A phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-151 cream 0.3% administered QD in subjects with chronic plaque psoriasis

35. 2019 – 2021 A long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults

36. 2019 – 2021 Phase II long-term extension study to assess the safety, tolerability, and efficacy of BI 730357 in patients with moderate-to-severe plaque psoriasis

37. 2019 – 2020 A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults

38. 2019 – 2020 A phase 3, double-blind, randomized, 8-week, vehicle-controlled efficacy and safety study of ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis

39. 2019 – 2021 A phase 3b multicenter, randomized, double-blind, double-dummy, active controlled study comparing the safety and efficacy of upadacitinib to dupilumab in adult subjects with moderate to severe atopic dermatitis

40. 2019 – 2021 A phase 2b randomized, double-blind, placebo-controlled, multicenter, dose-ranging study to evaluate the efficacy and safety profile of PF-06651600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06651600 and PF-06700841 in subjects with active non-segmental vitiligo

41. 2019 – 2020 A phase 3, multi-center, randomized, double-blind, vehicle-controlled, 2 arm, parallel group study comparing the safety and efficacy of IDP-120 Gel and IDP-120 vehicle gel in the treatment of acne vulgaris

42. 2019 – 2020 A phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis

43. 2019 – 2021 A phase 3, multi-center, randomized, double- blind, placebo-controlled study to assess the efficacy and safety of apremilast (CC-10004) in pediatric subjects from 6 through 17 years of age with moderate to severe plaque psoriasis

44. 2019 – 2021 A phase 2, multicenter, open-label extension study of the long-term safety of ARQ-151 cream 0.3% in adult subjects with chronic plaque psoriasis who have completed preceding study ARQ-151-201 phase 2 randomized controlled trial

45. 2019 – 2020 A 24-week multicenter, randomized, double-blind, parallel-group study comparing the efficacy and safety of ixekizumab to guselkumab in patients with moderate-to-severe plaque psoriasis

46. 2018 – 2020 A multicenter, open-label study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

47. 2018 – 2019 A multicenter, randomized, double-blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

48. 2018 – 2020 A phase 2b randomized, double-blind, placebo controlled, multicenter 12-week study with an additional 40-week follow-up assessment of efficacy, safety and tolerability of M1095 in subjects with moderate to severe chronic plaque-type psoriasis

49. 2018 – 2020 A randomized, double-blind, placebo- controlled, parallel-group study of GBR 830 in adult subjects with moderate to severe atopic dermatitis

50. 2018 – 2020 Phase II evaluation of safety, tolerability, and efficacy of BI 730357 in patients with moderate-to-severe plaque psoriasis

51. 2018 An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials

52. 2018 – 2020 A multicenter, randomized, double-blind, vehicle-controlled, study to evaluate the efficacy and safety of IDP-124 lotion for the treatment of moderate to severe atopic dermatitis in pediatric and adult subjects

53. 2019 A phase 3 randomized, placebo-controlled, double-blind study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis

54. 2018 – 2019 A phase 2b 12-week parallel group, double blind, vehicle-controlled study of the safety, efficacy and pharmacokinetics of ARQ-151 cream 0.3% and ARQ-151 cream 0.15% administered QD in subjects with chronic plaque psoriasis

55. 2018 – 2020 A multicenter, randomized, open label, efficacy assessor‐blinded study of risankizumab compared to secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy

56. 2018 – 2022 A multicenter, open-label, phase 3 study to evaluate the efficacy and safety of baricitinib in adult patients with moderate to severe atopic dermatitis

57. 2018 – 2021 A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of baricitinib in adult patients with moderate to severe atopic dermatitis

58. 2018 – 2020 A phase 3, multicenter, randomized, double-blind, placebo- and active comparator-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

59. 2018 – 2020 An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥6 months to <18 years of age with atopic dermatitis

60. 2017 – 2019 SOLACE: Canadian Humira® post marketing observational epidemiological study: Assessing Humira® real life effectiveness and impact on moderate to severe hidradenitis suppurativa (HS) burden of illness and health care resources utilization

61. 2017 – 2018 A phase 3, multi-center, randomized, double-blind, vehicle-controlled, 2 arm, parallel group study comparing the safety and efficacy of IDP-123 lotion and IDP-123 vehicle lotion in the treatment of acne vulgaris

62. 2017 – 2018 A randomized, multicenter study to evaluate the effect of secukinumab 300 mg s.c. administered during 52 weeks to patients suffering from new-onset moderate to severe plaque psoriasis as early intervention compared to standard treatment with narrow-band UVB (STEPIn study)

63. 2017 – 2018 A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab monotherapy in patients ≥12 to <18 years of age, with moderate-to-severe atopic dermatitis

64. 2017 – 2019 Tralokinumab monotherapy for moderate-to-severe atopic dermatitis ECZTRA 2

65. 2017 – 2019 A phase 3, multi-center, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp

66. 2017 – 2018 An open-label study assessing long-term safety of Olumacostat Glasaretil Gel in subjects with acne vulgaris

67. 2017 – 2018 A randomized, double-blind, vehicle-controlled, efficacy and safety study of Olumacostat Glasaretil Gel in subjects with acne vulgaris

68. 2017 – 2023 A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS)

69. 2017 – 2018 A multi-center, randomized, double-blind, parallel-group vehicle controlled study to compare the efficacy and safety of CD5789 50μg/g cream versus vehicle cream in subjects with acne vulgaris

70. 2017 – 2018 A randomised, double-blind, vehicle-controlled, phase IIb study to assess the efficacy and safety of topically applied DS107 cream to adults with mild to moderate atopic dermatitis

71. 2016 – 2019 A phase 2b multicenter, randomized, placebo-controlled, double-blind dose-ranging study to evaluate ABT-494 in adult subjects with moderate to severe atopic dermatitis

72. 2016 – 2018 A phase 2 single-arm open-label extension study to investigate safety with risankizumab in psoriatic arthritis subjects who have completed week 24 visit of study 1311.5

73. 2016 – 2017 A randomized, double-blind, placebo-controlled, multiple ascending dose study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of JTE-451 administered for 4 weeks in subjects with active plaque psoriasis

74. 2016 – 2018 A multicenter, 48-week, double-blind, placebo-controlled, parallel-group extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

75. 2016 – 2017 A phase 1 and 2 randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety, tolerability, efficacy, and exposure of up to 12 weeks of XPF-005 treatment in healthy volunteers and subjects with acne vulgaris

76. 2016 – 2017 A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

77. 2016 – 2020 PURE: A registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America (LACan)

78. 2016 – 2018 A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab versus placebo in patients with moderate-to-severe genital psoriasis

79. 2016 – 2017 A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis

80. 2016 – 2018 A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-approved Humira® in subjects with moderate to severe chronic plaque psoriasis

81. 2016 – 2017 Open label study to evaluate the efficacy of etanercept treatment in subjects with moderate to severe plaque psoriasis who have failed to respond, are intolerant, or lost a satisfactory response to apremilast

82. 2016 – 2017 BI 655066 versus ustekinumab and placebo comparators in a randomized double blind trial for maintenance use in moderate to severe plaque type psoriasis (UltIMMa-1)

83. 2016 – 2017 A phase 3, randomized, vehicle-controlled, double-blind, multicenter study to evaluate the safety and efficacy of once-daily CLS001 topical gel versus vehicle administered for 12 weeks to subjects with papulopustular rosacea with a 4 week follow-up period

84. 2016 Efficacy and safety of ivermectin 1% topical cream associated with brimonidine 0.33% topical gel in the treatment of moderate to severe rosacea

85. 2015 – 2016 A Phase 2b, randomized, double-blinded, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of tralokinumab in adult subjects with moderate-to-severe atopic dermatitis

86. 2015 – 2016 An open-label phase II study to evaluate the safety of lebrikizumab compared to topical corticosteroids in adult patients with persistent, moderate to severe atopic dermatitis

87. 2015 – 2019 A phase 3, multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis

88. 2015 – 2017 A phase 3, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of multiple dupilumab dose regimens administered as monotherapy for maintaining treatment response in patients with atopic dermatitis

89. 2015 – 2017 A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab dosing regimens in patients with moderate-to-severe plaque psoriasis

90. 2015 – 2016 A phase 2, randomized, double-blind, vehicle-controlled, dose-ranging study of DRM01B topical gel in subjects with acne vulgaris

91. 2015 – 2017 Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp or approximately 250cm2 on the chest

92. 2015 A phase 2, randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of PF-04965842 in subjects with moderate to severe psoriasis

93. 2015 – 2018 An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab clinical trials

94. 2015 – 2016 A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moderate-to-severe atopic dermatitis

95. 2015 – 2019 A 12-week multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of LY2439821 to etanercept and placebo in patients with moderate to severe plaque psoriasis with a long-term extension period

96. 2015 – 2017 Concomitant longitudinal evaluation of adalimumab with methotrexate in the real world: the CLEAR study

97. 2015 – 2016 A randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long-term safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

98. 2014 – 2015 Safety and efficacy of escalating doses of two LEO 43204 formulations applied once daily for two consecutive days on full face or approximately 250 cm2 (40 in2) on the chest in subjects with actinic keratosis

99. 2014 A multi-center, randomized, double-blind, parallel-group vehicle and active controlled study to compare the efficacy and safety of CD0271 0.3% / CD1579 2.5% topical gel versus topical gel vehicle in subjects with acne vulgaris

100. 2013 – 2014 OnabotulinumtoxinA in the treatment of forehead lines

101. 2013 – 2022 A 64-week, phase 3, randomized, placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 900222/MK-3222, followed by an optional long-term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis

102. 2013 – 2014 A study of the safety, tolerability and preliminary efficacy of DRM01B Topical Gel in healthy volunteers and subjects with acne vulgaris

103. 2012 – 2016 A phase 3 open-label study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa

104. 2012 – 2018 A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab

105. 2012 – 2016 A phase 3 study to evaluate the efficacy and safety of induction and maintenance regimens of brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis: AMAGINE-2

106. 2012 – 2015 A phase 3 study to evaluate the efficacy, safety, and effect of withdrawal and retreatment with brodalumab in subjects with moderate to severe plaque psoriasis: AMAGINE-1

107. 2012 – 2013 Effect of LEO 90100 on the HPA axis and calcium metabolism in subjects with extensive psoriasis vulgaris

108. 2012 – 2019 A multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of LY2439821 to etanercept and placebo in patients with moderate-to-severe plaque psoriasis

109. 2012 – 2019 A multicenter study with a randomized, double-blind, placebo-controlled induction dosing period followed by a randomized maintenance dosing period and a long-term extension period to evaluate the efficacy and safety of LY2439821 in patients with moderate-to-severe plaque psoriasis

110. 2012 – 2013 Multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ATX-101 (sodium doxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area

111. 2012 – 2014 A phase 3 multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa

112. 2012 – 2014 A randomized, double-blind, placebo-controlled, dose-ranging, phase 2b study of LY3009104 in patients with moderate-to-severe plaque psoriasis

113. 2012 – 2013 A phase 3 randomized, double-blind, 12-week vehicle-controlled, parallel-group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40-week investigator-blinded extension comparing the long-term safety of CD5024 1% cream versus azelaic acid 15% gel

114. 2011 – 2013 A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanercept, and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis

115. 2011 – 2013 Efficacy and safety comparison of adapalene 0.1% / benzoyl peroxide 2.5% gel associated with 200 mg doxycycline capsules versus vehicle gel associated with isotretinoin capsules in the treatment of severe acne

116. 2011 – 2016 A phase 3, multi-site, open-label study of the long term safety and tolerability of 2 oral doses of CP-690,550 in subjects with moderate to severe chronic plaque psoriasis

117. 2011 – 2014 A phase 3, multi-site, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of 2 oral doses of CP-690,550 in subjects with moderate to severe chronic plaque psoriasis

118. 2011 – 2013 A randomized, blinded assessor study to evaluate the efficacy and safety of etanercept 50 mg once weekly plus as needed topical therapy versus etanercept 50 mg twice weekly in subjects with moderate to severe plaque psoriasis (Sub-Investigator)

119. 2010 – 2012 A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in subjects with moderate to severe plaque psoriasis

120. 2010 – 2016 A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis

121. 2010 – 2011 A multi-center, randomized, vehicle-controlled, double-blind, study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris

122. 2010 A 12-week efficacy evaluation of WBI-1001 cream in patients with atopic dermatitis: a multi-centered, double-blinded study (6-week placebo-controlled phase followed by a 6-week non-placebo-controlled phase) (Sub-Investigator)

123. 2010 – 2021 A 10-year, post-marketing, observational, registry of HUMIRA® (adalimumab) in adult patients with chronic plaque psoriasis (Ps)

124. 2010 – 2014 Long-term safety extension study of apremilast (CC-10004) in subjects who completed the treatment phase of the extension study CC-10004-PSOR-005E

125. 2010 – 2012 Clinical evaluation of the miraDry system in subjects with hyperhidrosis (Sub-Investigator)

126. 2010 – 2011 A phase 3, multicenter, randomized, double-blind study evaluating the safety and efficacy of IDP-108 topical solution versus vehicle in subjects with mild to moderate onychomycosis of the toenails

127. 2009 – 2011 A multi-center, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of tazarotene foam, 0.1% in subjects with acne vulgaris

128. 2009 – 2019 A multicenter, open registry of patients with psoriasis who are candidates for systemic therapy including biologics” with the study name of psoriasis longitudinal assessment and registry

129. 2009 – 2010 A phase 3b, randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of imiquimod cream following cryosurgery for the treatment of actinic keratoses

130. 2009 – 2010 A phase 2B, multicenter, treatment-arm blind, safety and efficacy 28-week extension study of apremilast (CC-10004) in subjects who completed the treatment phase of the core study CC-10004-PSOR-005

131. 2009 – 2010 LEO 29102 cream in the treatment of atopic dermatitis. A phase 2, proof of concept and dose finding study, investigating treatment efficacy of LEO 29102 cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g), LEO 29102 cream vehicle, and Elidel® (pimecrolimus) cream 10 mg/g, after cutaneous administration twice daily for 4 weeks. An international, multi-centre, prospective, randomised, double-blind, 7-arm, vehicle-controlled, parallel group study

132. 2008 – 2009 Phase 2a randomized, double-blind, vehicle-controlled, intra-individual comparison trial assessing safety, toleration, pharmacokinetics and pilot efficacy of 4 weeks treatment with topical CP-690,550 in chronic plaque psoriasis

133. 2008 – 2009 A phase 3 multicenter, randomized, double-blind, active and vehicle-controlled study of the safety and efficacy of duac low-dose gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris

134. 2008 – 2010 A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, efficacy and safety study of apremilast (CC-10004) in subjects with moderate-to-severe plaque-type psoriasis (core study)

135. 2008 – 2012 A phase 3, multi-center, open-label extension study designed to describe the safety, tolerability, and efficacy of long-term administration of the human monoclonal antibody against IL-12 in subjects with moderate to severe chronic plaque psoriasis

136. 2008 – 2009 A phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two dosing regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis

137. 2007 – 2008 A multi-center, randomized, double-blind, parallel group study to demonstrate the efficacy and safety of adapalene lotion, 0.1% compared with vehicle lotion in subjects with acne vulgaris

138. 2007 – 2008 Efficacy and safety of ASF-1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, double-blind, vehicle- and placebo-controlled, parallel groups, multi-centre trial

139. 2007 – 2010 Efficacy and safety of alefacept in combination with narrow-band UVB (nbUVB) compared to alefacept alone in subjects with moderate to severe chronic plaque psoriasis (Sub-Investigator)

140. 2007 – 2008 A phase IIa, randomized, double-blind, placebo controlled study to evaluate the clinical efficacy, safety and pharmacokinetics of three different doses of BMS-582949 given orally to subjects with moderate to severe plaque psoriasis

141. 2007 – 2008 A Canadian open-label access program to evaluate the safety and the effectiveness of adalimumab when added to inadequate therapy for the treatment of psoriasis

142. 2007 – 2009 A phase III, randomized, multicentre, double-blind, placebo and ciclosporin controlled study of ISA247 in plaque psoriasis patients

143. 2007 – 2009 A phase 3, multicenter, randomized study comparing CNTO 1275 and etanercept for the treatment of moderate to severe plaque psoriasis

144. 2007 – 2008 A multi-center, randomized, double-blind, parallel-group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris

145. 2006 – 2013 Observational post-marketing safety surveillance registry of Enbrel® (etanercept) for the treatment of psoriasis (OBSERVE-5)

146. 2006 – 2012 A phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis

147. 2006 – 2009 RESTORE (Raptiva® (efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, open-label, multi-centre, phase IV study of subcutaneously administered Raptiva® (efalizumab) in the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for treatment with Raptiva® (Sub-Investigator)

148. 2006 – 2007 A phase IIa randomized, double-blind, placebo-controlled, parallel group, multi-center study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RWJ-445380 administered to patients with plaque psoriasis

149. 2006 – 2007 A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study of XXXX in subjects with moderate-to-severe plaque-type psoriasis

150. 2006 – 2007 A phase 3, randomized, double-blind study to evaluate the efficacy and safety of BID application of XXXX cream 0.1% versus XXXX cream vehicle in the treatment of psoriasis

151. 2006 – 2007 A phase 2, multicenter, randomized, double-blind, placebo-controlled trial of XXXX, a fully human anti-IL-12 monoclonal antibody, administered subcutaneously, in subjects with active psoriatic arthritis

152. 2005 – 2006 An observational, multicentre open-label study for subjects receiving XXXX for moderate to severe chronic plaque psoriasis

153. 2002 – A multicentre, single arm prospective, open label study to assess the safety of Elidel (SDZ ASM 981 – pimecrolimus 1% cream) in patients with atopic dermatitis (Rainbow Study)